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Small alveolar macrophages are infected
preferentially by HIV and exhibit impaired
phagocytic function
KC Jambo1,2, DH Banda1, AM Kankwatira1, N Sukumar3, TJ Allain4, RS Heyderman1,2,4,
DG Russell3 and HC Mwandumba1,2,4
HIV-1-infected persons are at higher risk of lower respiratory tract infections than HIV-1-uninfected individuals. This
suggests strongly that HIV-infected persons have specific impairment of pulmonary immune responses, but current
understanding of howHIValters pulmonary immunity is incomplete. Alveolarmacrophages (AMs), comprising small and
large macrophages, are major effectors of innate immunity in the lung. We postulated that HIV-1 impairs pulmonary
innate immunity through impairment of AMphysiological functions. AMswere obtained by bronchoalveolar lavage from
healthy, asymptomatic, antiretroviral therapy-naive HIV-1-infected and HIV-1-uninfected adults. We used novel assays
to detect in vivo HIV-infected AMs and to assess AM functions based on the HIV infection status of individual cells. We
show that HIV has differential effects on key AM physiological functions, whereby small AMs are infected preferentially
by the virus, resulting in selective impairment of phagocytic function. In contrast, HIV has a more generalized effect on
AM proteolysis, which does not require direct viral infection. These findings provide new insights into how HIV alters
pulmonary innate immunity and the phenotype of AMs that harbors the virus. They underscore the need to clear this HIV
reservoir to improve pulmonary immunity and reduce the high incidence of lower respiratory tract infections in HIV-1-
infected individuals.
INTRODUCTION
HIV infects a variety of different cell types that have crucial
roles in host immunity.1–3 CD4þ T lymphocytes are the main
host cell in chronic HIV infection and the effects of HIV on
adaptive immunity have been well documented.4,5 HIV
infection of other cell types such as macrophages, monocytes,
and circulating dendritic cells has, however, been less
well studied,6 mainly owing to the shortage of reliable methods
for detecting in vivo HIV-infected cells within these cell
populations.
Alveolar macrophages (AMs) are the most abundant
phagocytes and major effectors of innate immunity in the
alveolar space in the lung.7 Recent reports suggest that two
macrophage populations, small and large, exist in the alveolar
space.8,9 AMs perform a variety of important innate functions,
including phagocytosis, superoxide burst, and proteolysis.10
Impaired AM function in smokers is associated with increased
risk of pulmonary infections and is implicated in the
pathogenesis of chronic obstructive pulmonary disease.11,12
These observations highlight the importance of AMs in defence
against respiratory pathogens.
Infection with HIV increases the risk of lower respiratory
tract infections.13,14 AMs are susceptible to HIV infection
because they express on their surface CD4, CCR5, and CXCR4
receptors, which mediate HIV entry into cells.15 Previous
approaches have investigated the effect of HIV onAM function
at a population level16 or have used in vitro macrophage
infectionmodels.17 Consequently, data on the effects of HIV on
the physiological functions of AMs are conflicting. We and
others have previously reported unimpaired phagocytic ability
of AMs inHIV-infected individuals,18–20 but other studies have
documented a reduction in the phagocytic capacity of
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macrophages.21–24 Similarly, although some groups have
reported normal killing of bacteria by primary macrophages
from HIV-infected individuals,25 others have shown reduced
killing capacity of AMs in HIV-infected individuals.26,27 Most
of these studies assessed only a single AM function and none of
them related HIV infection with alterations in function at the
level of the individual cell.
To advance current understanding of the direct effect of HIV
on AM physiological functions, we developed novel flow
cytometry-based assays to detectHIV-infectedmacrophages by
fluorescence in situ hybridization (FISH) and to measure
macrophage phagocytic capacity, phagosomal superoxide
burst, and proteolysis at single-cell level using reporter beads.
We conducted a prospective cross-sectional study in healthy,
asymptomatic HIV-1-infected and HIV-1-uninfected adults to
identify specific defects inAMantimicrobial functions thatmay
predispose HIV-1-infected individuals to lower respiratory
tract infections.
RESULTS
Clinical characteristics
Between July 2011 and March 2013, we recruited and
performed bronchoalveolar lavage (BAL) on 34 healthy,
asymptomatic, and antiretroviral therapy-naive HIV-1-
infected and 45 healthy HIV-1-uninfected adult volunteers
(Table 1). Participants were predominantly men (67%) with a
mean age of 31 years (range 20–59). Three HIV-1-infected
(8.8%) and nine HIV-1-uninfected (20%) participants were
smokers. The median peripheral blood CD4þ T-lymphocyte
counts were 399 cells ml 1 (interquartile range (IQR)¼ 270–
573) and 623 cells ml 1 (IQR¼ 536–723) for HIV-1-infected
and HIV-1-uninfected individuals, respectively.
Characterization of AMs
Whole BAL cells from participants were analyzed by flow
cytometry. On the basis of their forward scatter and side scatter
characteristics and labeling with the macrophage marker, anti-
CD206 (for mannose receptor), and the T-lymphocyte marker,
anti-CD3 (for T-cell receptor), we defined macrophage and
lymphocyte populations, and identified distinct small and large
AM subpopulations both in HIV-1-uninfected and HIV-1-
infected individuals (Figure 1a,b,c) as previously reported by
others.8,9We found no significant difference in the proportions
of these cells between HIV-1-uninfected and HIV-1-infected
persons (median, small AMs¼ 32.32% (IQR¼ 23.5–43.8%)
vs. 30.25% (IQR¼ 24.8–35.0%), P40.05; large AMs¼
69.6% (IQR¼ 65.0–75.2%) vs. 67.7% (IQR¼ 56.2–76.5%);
Figure 1d).
To confirm that the small AMs were not inflammatory
monocytes or dendritic cells, we measured the proportion and
magnitude of expression of monocyte, macrophage, and
dendritic cell markers, including the lipopolysaccharide co-
receptor (CD14), FcgRIII (CD16), mannose receptor (CD206),
transferrin receptor (CD71), major histocompatibility complex
class II (HLA-DR), integrin-aX (CD11c) and interleukin-3
receptor a-chain (CD123).We found that small AMs expressed
predominantly the classical macrophage markers CD71 and
CD206, and the pattern of expressionwas similar to that of large
AMs. The proportion and magnitude of expression of the
classical monocyte and dendritic cell markers CD14 and
CD123, respectively, by small AMs was low (Figure 2a,b).
However, there were significant differences in the proportions
of surface marker expression by small and large AMs: CD206
(median¼ 58.0% (IQR¼ 36.5–78.3%) vs. 85.3% (IQR¼ 61.6–
96.7%),P¼ 0.03), CD71 (median¼ 82.3% (IQR¼ 48.3–89.3%)
vs. 97.1% (IQR¼ 85.6–99.0%), P¼ 0.03), and CD16
(median¼ 51.9% (IQR¼ 21.8–70.5%) vs. 66.1% (IQR¼
32.9–92.1%), P¼ 0.03). There were no significant differen-
ces in expression of CD14 and HLA-DR between small
and large AMs (Figure 2a). We also found that the magnitude
of CD206 expression by small AMs was significantly
lower compared with large AMs (median log geometric
mean fluorescence intensity¼ 1.56 (IQR¼ 1.36–1.70) vs.
1.86 (IQR¼ 1.72–2.10), P¼ 0.03), but was not significantly
different for the other markers evaluated (Figure 2b).
HIV preferentially infects small AMs
To determine the frequency of HIV-infected AMs in BAL from
asymptomatic HIV-infected individuals, we used a novel flow
cytometry-based FISH assay developed by our group to detect
HIV-infected cells. We validated the assay for label specificity
using uninfected human monocyte-derived macrophages and
human monocyte-derived macrophages infected in vitro with
the macrophage-tropic HIV-1 strain BaL (Figure 3a). We then
used the FISH assay to determine the relative distribution of
HIV in BAL macrophages and lymphocytes from six
participants with chronic HIV-1 infection by flow
cytometric analysis of whole BAL cells, and gating on the
macrophage and lymphocyte populations, respectively. The
identity of T cells was confirmed by labeling with anti-CD3
Table 1 Characteristics of subjects enrolled in the study
HIV-1-uninfected adults n¼ 45 HIV-1-infected adults n¼ 34 P-values
Sex, female:male 4:21 14:11 0.0002a
Age, mean years (range) 38 (20–59) 31 (20–51) 0.9672
CD4 count, median cellsml 1 (range) 623 (536–723) 399 (270–573) o0.0001
HIV plasma VL, copiesml 1 (range) NA 21113 (5803–91323)
WHO stage NA Stage 1
NA, not applicable; VL, viral load; WHO, World Health Organisation.
aFisher’s exact test.
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antibody (Figure 3b). In all six individuals, we detected HIV-
infected AMs and T cells (Figure 3b); the percentage of HIV-
infected cells was higher among AMs than among T cells
(median¼ 1.55% (IQR¼ 0.64–3.45%) vs. 0.13% (IQR¼ 0.04–
0.59%), P¼ 0.03; Figure 3c). However, the frequency of HIV-
infected T cells was consistent with what has been reported
previously.28
Analysis of adherent BAL cells showed that small AMs
constituted the majority of HIV-infected macrophages in BAL
(Figure 4a) andB1% of adherent AMs from participants with
chronic HIV infection were HIV infected (median¼ 1.0%
(IQR¼ 0.5–1.3%); Figure 4b). We used adherent cells
specifically because they consisted of a relatively pure and
enriched population of AMs that were used in all subsequent
phagosomal function assays. In addition, analysis of whole BAL
cells from a subset of five participants revealed a higher
frequency of HIV-infected AMs than in adherent BAL cells,
suggesting that HIV-infected cells adhere less well to plastic
(mean±s.e.m., whole BAL 3.7%±1.3 vs. adherent BAL
1.3%±0.3; P¼ 0.06; Figure 5a,b). However, as with
adherent cells, the proportion of HIV-infected AMs in
whole BAL was higher among the small compared with
that among the large AMpopulation (Figure 5a). Furthermore,
HIV-infected AM showed markedly reduced expression of
CD206 (median fluorescence intensity (MFI)¼ 3.4 (IQR¼
2.4–69.2) vs. 87.6 (IQR¼ 42.2–223.3), P¼ 0.03), HLA-DR
(MFI¼ 27.4 (IQR¼ 9.4–80.1) vs. 202.5 (IQR¼ 10.0–236.3),
P¼ 0.03), and CD71 (MFI¼ 6.2 (IQR¼ 4.7–9.2) vs. 48.9
(IQR¼ 36.7–49.6), P¼ 0.002), but similar levels of CD45
(MFI¼ 70.7 (IQR¼ 46.4–247.3) vs. 70.8 (IQR¼ 41.3–284.0),
compared with HIV-uninfected AMs (Figure 6a,b). Reduced
expression of CD206 and HLA-DR by HIV-infected human
myeloid cells has been reported previously22,29 and may
represent mechanisms by which HIV alters host innate
immunity and accessory cell functions.
Comparison of phagocyte function between small and
large AMs
Following identification of small and large AM populations, we
investigated whether there were functional differences between
them by assessing the ability of these cells to internalize Alexa
405-labeled, IgG-coated reporter beads. We found that the
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Figure 1 Definition of cell populations in bronchoalveolar lavage (BAL) by flow cytometry. Themajor cell populations in whole BALwere defined initially
by their forward scatter (FSC) and side scatter (SSC) characteristics. The identities of the cell populations were then confirmed by demonstrating the
gated cell populations labeled with anti-CD206 (macrophage marker) and anti-CD3 (T-lymphocyte marker), respectively. (a) Representative pseudo-
color plot showing the gating strategy for macrophage and lymphocyte populations. (b) Representative dot plot showing the major cell populations in
whole BAL (macrophages¼blue and lymphocytes¼ red). (c) Labeling of gated cell populationswithmacrophage andT-lymphocytemarkers, and (d) the
proportion of small and large alveolar macrophages (AMs) in BAL from HIV-1-infected and HIV-1-uninfected individuals. Data were analyzed using the
Mann–Whitney U-test; black horizontal bars represent medians (HIV , n¼ 19; HIVþ , n¼22).
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proportion of large AMs that internalized reporter beads was
significantly higher than that of small AMs, both in HIV-1-
uninfected and HIV-1-infected persons (HIV-uninfected
persons: large AM median¼ 70.2% (IQR¼ 58.4–74.0) vs.
small AM median¼ 55.1% (IQR¼ 41.8–65.3), Po0.0001;
HIV-infected persons: largeAMmedian¼ 65.8% (IQR¼ 59.6–
71.9) vs. small AM median¼ 58.9% (IQR¼ 49.1–68.9),
Po0.0001; Figure 7a). We found no significant differences
in phagosomal superoxide burst activity between small and
largeAMs fromHIV-1-infected andHIV-1-uninfected persons
(Figure 7b). In contrast, we found lower phagosomal bulk
proteolytic activity in small compared with large AMs from
HIV-1-uninfected persons (mean activity index¼ 0.16 (95%
confidence interval (95%CI)¼ 0.1–0.2) vs. 0.18 (95%CI¼ 0.2–
0.2), P¼ 0.002), but this was not the case in HIV-infected
persons (Figure 7c). These data show that compared with large
AMs, small AMs from both HIV-1-infected and HIV-1-
uninfected individuals have reduced phagocytic capacity. The
data also suggest that infection with HIV-1 may impair
phagosomal bulk proteolytic activity in both small and large
AMs, and this may explain the lack of a significant difference in
the magnitude of proteolytic function between these two AM
populations in HIV-infected individuals.
Comparison of phagocyte function based on participant
HIV status and AM size
Next, we assessed the association between the HIV status of
participants and AM function at both the total macrophage
population level and as separate populations of small and large
AMs irrespective of the infection status of the AMs. Analysis of
total AM populations revealed no significant differences
between HIV-1-uninfected and HIV-1-infected participants
in the proportions of AMs that internalized reporter beads
(median¼ 65.2% (IQR¼ 54.8–71.2%) vs. 62.8% (IQR¼ 56.1–
70.2%), P40.05) and in the magnitude of superoxide burst
(mean activity index¼ 0.10 (95% CI 0.1–0.1) vs. 0.15 (95% CI
0.1–0.2), P40.05; Figure 7a,b). In contrast, we found that the
total AM population from HIV-1-infected participants had
reduced phagosomal bulk proteolytic activity compared with
those from HIV-1-uninfected participants (mean activity
index¼ 0.12 (95% CI 0.1–0.1) vs. 0.17 (95% CI 0.1–0.2),
P¼ 0.04; Figure 7c). Comparisons of small versus large AM
subpopulations revealed reduced superoxide burst and bulk
proteolytic activity in large AMs but not in small AMs from
HIV-1-infected compared with HIV-1-uninfected participants
(mean activity index¼ 0.09 (95% CI 0.1–0.1) vs. 0.17 (95% CI
0.1–0.2), P¼ 0.03 for superoxide burst (Figure 7b) and mean
activity index¼ 0.13 (95%CI 0.1–0.2) vs. 0.18 (95%CI 0.2–0.2),
P¼ 0.05 for bulk proteolysis (Figure 7c)). These data suggest
that HIV-1 is associated with impaired phagosomal activities
within the large AM population but not the small AM
population from HIV-infected individuals.
Comparison of phagocyte function based on the size and
HIV infection status of individual AM
The previous analysis did not discriminate between HIV-
infected and HIV-uninfected AMs. To determine whether the
impact of HIV on AM function in HIV-1-infected individuals
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Figure 2 Surface marker expression by small and large alveolar macrophages (AMs) from healthy HIV-1-uninfected participants. Bronchoalveolar
lavage (BAL) cellswere stainedwith anti-CD206 fluorescein isothiocyanate (FITC), anti-CD71PE-Cy5, anti-HLA-DRAlexa fluor 700, anti-CD16PE, anti-
CD14 PE-Cy7, anti-CD11C PE, and anti-CD123 PE-Cy5, and analyzed by flow cytometry. (a) Proportions of small and large AMs expressing these
surface markers. (b) The magnitude of surface marker expression by large and small AMs as measured by the geometric mean fluorescence intensity.
Data were analyzed using the Wilcoxon matched-pairs signed-ranked test; black horizontal bars represent medians (HIV , n¼ 10).
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was specific to HIV-infected cells or a property of all AMs
isolated from this tissue environment, we assessed the
phagocytic capacity and phagosomal functions of AMs based
on the HIV infection status of individual cells. First, we
compared, irrespective of cell size, the ability of HIV-infected
and HIV-uninfected AMs from the same individual, to
internalize reporter beads and to perform phagosomal super-
oxide burst and bulk proteolysis (Figure 8a). We found that
overall HIV-infected AMs had increased phagocytic capacity
compared with HIV-uninfected AMs (median¼ 72.3%
(IQR¼ 68.5–75.4%) vs. 62.4% (IQR¼ 56.1–70.0%),
P¼ 0.004; Figure 8b). However, we found no difference in
the magnitude of phagosomal superoxide burst (mean activity
index¼ 0.10 (95% CI¼ 0.05–0.14) vs. 0.10 (95% CI¼ 0.06–
0.14), P40.05) or bulk proteolytic activity (mean activity
index¼ 0.11 (95% CI¼ 0.04–0.18) vs. 0.12 (CI¼ 0.08–0.16),
P40.05) between HIV-infected and HIV-uninfected AMs
(Figure 8c,d).
Second, we assessed the impact ofHIV on the phagocytic and
phagosomal functions of HIV-infected AMs by cell size. We
found that overall, small AMs had reduced phagocytic capacity
irrespective of their HIV-infection status compared with large
AMs. However, we found that the difference in phagocytic
capacity between small and large AMs was greater in HIV-
infected AMs (median¼ 43.0% (IQR¼ 28.6–58.6) vs. 80.0%
(IQR¼ 76.4–84.5), Po0.0001) compared with HIV-
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Figure 3 Detection of HIV-infected human cells by fluorescence in situ hybridization (FISH). The presence of HIV mRNA in human monocyte-derived
macrophages (hMDMs) infected experimentally with the macrophage-tropic strain BaL and in bronchoalveolar lavage (BAL) cells isolated from healthy
HIV-infected individuals was detected by flow cytometry using FISH probes against HIV-gag mRNA. (a) Representative pseudo-color plots from
experiments to validate the FISH assay for label specificity using uninfected hMDMs and hMDMs infected in vitro with HIV. (b) Whole BAL cells were
colabeled with HIV-gagQuasar 670 FISH probes and anti-CD3 antibody, and analyzed by flow cytometry. Alveolar macrophages (AMs) and lymphocyte
populations were identified by their forward scatter (FSC) and side scatter (SSC) characteristic properties. T cells were confirmed by CD3 positivity. (c)
Detection of HIV-infected cells in AMs and T cells in whole BAL from the same individual (color coded). Data were analyzed using theWilcoxonmatched-
pairs signed-rank test; black horizontal bars represent medians (n¼ 6).
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uninfected AMs (median¼ 54.5% (IQR¼ 46.4–58.0) vs. 65.6%
(IQR¼ 59.1–72.2), P¼ 0.003; Figure 8b). We also observed
that the phagocytic capacity of HIV-infected small AMs was
less than that of HIV-uninfected small AMs, although this did
not reach statistical significance (Figure 8b). Interestingly, the
phagocytic capacity of HIV-infected large AMs was
significantly greater than that of HIV-uninfected large AMs
(80.0% (IQR¼ 76.4–84.5) vs. 65.6% (IQR¼ 59.1–72.2),
Po0.0001). We found no difference in phagosomal
superoxide burst or bulk proteolytic activity between small
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Figure 4 Small alveolar macrophages (AMs) are the dominant macrophage population harboring HIV in the alveolar space. Adherent AMs isolated
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Figure 5 HIV-infected alveolar macrophages (AMs) do not adhere well to plastic. Whole bronchoalveolar lavage (BAL) and adherent BAL cells were
stained with HIV-gagQuasar 670 fluorescence in situ hybridization (FISH) probes and analyzed by flow cytometry. On the basis of forward scatter (FSC)
and side scatter (SSC) characteristics of the cells, AMs were identified and the frequency of HIV-infected cells determined. (a) Representative pseudo-
color plots showing the gating strategy and the frequency of HIV-infected AMs in whole BAL and adherent BAL cells from the same asymptomatic HIV-
infected individual. (b) Comparison of the frequencies of HIV-infected AMs in whole BAL and adherent BAL cells from the same individuals. Data were
analyzed using the paired Student’s t-test (n¼ 5).
ARTICLES
MucosalImmunology | VOLUME 7 NUMBER 5 | SEPTEMBER 2014 1121
and large HIV-infected or HIV-uninfected AMs (Figure 8c,d).
These findings suggest that HIV has differential effects on AM
function whereby HIV-infected small AMs exhibit selective
impairment of phagocytic function. In contrast, HIV has a
more generalized effect on AM proteolysis, which is not
restricted toHIV-infected cells but affects all AMs isolated from
this tissue environment.
DISCUSSION
In this study, we assessed the impact of HIV on the
physiological functions of AMs, major contributors to innate
immunity in the lower respiratory tract. We have shown that
small and large AMs are present in BAL from both HIV-1-
infected and HIV-1-uninfected individuals, and that in HIV-
infected individuals small AMs are the predominant phenotype
that harbors HIV.
Small macrophages with monocytic characteristics have
previously been identified in sputum and BAL from patients
with cystic fibrosis.8,9 In addition, it has been shown that non-
classicalmonocytes expressingCD16 in the peripheral blood are
permissive to infection and preferentially harbor HIV-1
in vivo.30,31 We wondered, therefore, whether the population
of small, HIV-preferred macrophages we had identified in BAL
were inflammatory monocytes. We found that apart from the
size difference, small AMs expressed the same array of surface
markers typical ofmacrophages and expressed by the large AMs
such as CD206 and CD71, which are not expressed on
inflammatory monocytes.32,33 Functionally, however, we have
shown that small AMs from both HIV-1-infected and HIV-1-
uninfected individuals have reduced phagocytic capacity and
bulk proteolytic activity than large AMs. This is consistent with
the findings of Lay et al.,34 who reported that the phagocytic
capacity of airwaymaturemacrophageswas significantly greater
than airway immaturemacrophages in healthy participants.We
speculate that the functional differences observed could be
attributed to the differentiation stage of the AMs, small AMs
maybe immaturemacrophages differentiating into largemature
AMs, and originate either from peripheral blood monocytes or
from progenitor cells within the lung parenchyma.35,36
Only a small proportion of AM in asymptomatic chronically
HIV-1-infected adults are infected with HIV. This is consistent
with previous studies that reported low frequency of HIV-
infected AMs in chronically HIV-infected individuals.37,38 We
have demonstrated that impaired phagocytosis is specific to
HIV-infected small AMs, which also have reduced expression
of HLA-DR and CD206, an important pathogen recognition
receptor.39 In the current study, we did not determine whether
the virus preferentially infects AMs with this surface marker
phenotype orwhether the induction of this phenotype occurred
post infection. However, Koziel et al.22 have reported
previously that in vitro HIV infection of AMs from healthy
individuals significantly reduced mannose receptor (CD206)
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Figure 6 Surface marker expression by HIV-infected alveolar macrophages (AMs) in whole bronchoalveolar lavage (BAL) from HIV-1-infected
participants.Whole BAL cells stainedwith anti-CD206 fluorescein isothiocyanate (FITC), anti-HLA-DRAF700, anti-CD45 PE, and anti-CD71 PE-Cy5 for
surface marker expression, and HIV-gagQuasar 670 fluorescence in situ hybridization (FISH) probes to detect HIV-infected cells were analyzed by flow
cytometry. AMs were identified by their forward scatter (FSC) and side scatter (SSC) characteristics and the expression of CD206, HLA-DR, CD45 and
CD71 by HIV-infected and HIV-uninfected AMs from the same individual was determined. (a) Representative histograms showing expression of CD206,
HLA-DR, CD45 and CD71 by HIV-infected and HIV-uninfected AMs. (b) Expression of CD206, HLA-DR, CD45 and CD71 by HIV-infected and
HIV-uninfected AMs. Data were analyzed by the Wilcoxon matched-pairs signed-ranked test (n¼6).
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endocytosis and Pneumocystis carinii (Pneumocystis jirovecii)
binding and phagocytosis compared with HIV-uninfected
AMs. These in vitro findings suggest that reduced expression of
CD206 and HLA-DR by HIV-infected small AMs occurred
post infection and may represent potential mechanisms by
which HIV alters pulmonary innate immunity and AM
physiological and accessory functions.
We have shown that impaired phagosomal proteolytic
activity is not restricted to HIV-infected AMs but is a property
of all AMs in this tissue environment. Although our data do not
address themechanisms responsible for the reduced proteolytic
activity of AMs from HIV-1-infected individuals, Yates et al.40
reported reduced phagosomal proteolysis following activation
of murine bone marrow-derived macrophages by interferon-g
and concluded that activation reduces the early phagosomal
hydrolytic capacity of macrophages. Asymptomatic HIV-1-
infected individuals have high levels of interferon-g in the
lung41 and have highly activated AMs compared with HIV-
uninfected individuals.42 We speculate that the reduced
phagosomal proteolytic activity observed in AMs from
HIV-1-infected individuals may be due to interferon-g-
induced activation of these cells. Although AMs may not be
the dominant antigen-presenting cells in the lung due to low
expression of costimulatory molecules such as CD80 and
CD86,43 reduced proteolytic function coupled with reduced
HLA-DR expression byHIV-infectedAMswould further affect
their ability to process and present antigens to T cells, thereby
contributing to impaired bronchoalveolar CD4þ T-cell
responses.44,45 It would also limit the immune recognition
of HIV-infected AM, which will blunt the effector functions
and, potentially, reduce clearance of infected cells.
In this study, we did not determine whether HIV infection of
AMs is productive and generates progeny virus. In addition, we
did not look directly at the microbial killing behavior of AMs
using infectious agents but restricted our preliminary func-
tional analysis to short-term, well-defined and characterized
assays such as proteolysis and superoxide burst. This is because
we are currently unable to safely perform culture of infectious
agents beyond short-term incubations in the clinical labora-
tories in Malawi. However, we intend to address these
important shortfalls in the future and to directly assess the
microbial killing behavior of AMs infected in vitro with
respiratory pathogens such as Mycobacterium tuberculosis.
In conclusion, we have shown that HIV affects innate
immunity in the lower respiratory tract through impairment of
key AM physiological functions. The ability to detect HIV-
infected AMs and to assess macrophage function based on the
HIV infection status of individual cells has enabled us to
establish that impairment of some phagocyte functions such
as phagocytosis is selective and predominantly affects
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HIV-infected small AMs, whereas impairment of other
functions such as phagosomal proteolysis is generalized and
affects all AMs from HIV-1-infected individuals. AMs are
infected with HIV early during the course of HIV infection46
and are relatively resistant to the cytopathic effects of HIV,
making them suitable reservoirs for the virus.47 Therefore,
persistent HIV infection of AMs will result in early and
protracted impairment of pulmonary innate and adaptive
immunity. Impaired AM innate functions may explain, at least
in part, the high incidence of lower respiratory tract infections
seen in HIV-1-infected individuals. Whether initiation of
antiretroviral therapy, particularly using agents that target viral
integration within the host genome, reverses this immune
defect remains to be determined.
METHODS
Subjects. The study was conducted at the Queen Elizabeth Central
Hospital, a large teaching hospital in Blantyre, Malawi. Participants
were healthy adults (Z18 years) comprising asymptomatic
HIV-1-infected and HIV-1-uninfected volunteers with no clinical
evidence of active disease and willing to undergo bronchoscopy
specifically for research purposes. All HIV-1-infected participants
were antiretroviral therapy naive at the time of recruitment. Exclusion
criteria were use of immunosuppressive drugs, anemia (Hbo8 g dl 1)
and known or suspected pregnancy. The study was approved by the
research ethics committees of the College of Medicine in Malawi, the
Liverpool School of Tropical Medicine and Cornell University. All
participants provided written informed consent.
BronchoscopyandprocessingofBAL. Bronchoscopy and BALwere
performed as previously described.44,48 Because of limitations in cell
numbers, not all the assays were performed on cells obtained from
every participant.
Immunophenotyping and enrichment of AMs. Immunophenotyping
was performed on 5 105 whole BAL cells before any enrichment step.
Cells were stained with anti-CD206 FITC, anti-CD3 PE-Cy5, anti-
CD16 PE, anti-CD71 PE-Cy5, anti-CD14 PE-Cy7, anti-CD11C PE,
anti-CD123 PE-Cy5, and anti-HLADR AlexaFluor700 (all BD
Bioscience, Oxford, UK), and acquired on a CyAn ADP 9-Colour flow
cytometer (Beckman Coulter, Brea, CA). Data were analyzed using
FlowJo software version 7.6.4 (Tree Star, San Carlos, CA). For each
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reporter beads tomeasure phagocytosis, superoxide burst, and bulk proteolysis. The cells were then stainedwithHIV-gagQuasar 670-labeled probes by
fluorescence in situ hybridization (FISH) to detect HIV-infected AMs and analyzed by flow cytometry. (a) Representative flow cytometry pseudo-color
plots showing phagocytosis of beads by small and large, HIV-infected, and HIV-uninfected AMs. The plots show four different cell populations: HIV-
infected cells without beads (Q1), HIV-infected cells with beads (Q2), HIV-uninfected cells with beads (Q3), andHIV-uninfected cells without beads (Q4).
(b) Phagocytosis of reporter beads by HIV-infected and HIV-uninfected AMs from the same HIV-infected individuals (n¼ 14). (c,d) Phagosomal
superoxide burst and bulk proteolytic activities, respectively, in HIV-infected compared with HIV-uninfected AMs (n¼10). The data in panels c and d are
expressed as the Activity Index, which is the ratio of relative fluorescence units of the substrate fluorescence divided by the calibration fluorescence to
ensure dosage correction for minor variations in bead number. Data were analyzed using matched-pair one-way analysis of variance with Bonferroni
correction; black horizontal bars represent medians (b) and means (c,d).
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stained sample analyzed, the MFI for each parameter was normalized
to its respective unstained control. AMs were enriched from whole
BAL cells by adherence to 499% purity as described previously.49
FISH assay for detection of HIV-infected AMs. HIV-infected cells
were detected by flow cytometry using a modification of the Stellaris
RNA FISH assay targeting HIV gag mRNA using a pool of 48
fluorophore-labeled oligonucleotides50 (Biosearch Technologies,
Novato, CA). Briefly, adherent AMs were fixed in 0.5ml of 3.7%
formaldehyde for 15min. Fixed cells were washed and permeabilized
in 70% ethanol overnight at 4 1C. Cells were then washed in buffer
(10% formamide, 20 saline sodium citrate, and nuclease-free water)
and resuspended in hybridization buffer (10% formamide, 20 saline
sodium citrate, 10% dextran sulfate with 1mgml 1 Escherichia coli
tRNA, 200mgml 1 RNase-free bovine serum albumin, and 2mM
vanadyl ribonucleoside complex). HIV-1-gag Quasar 670-labeled
probes were incubated with the cells for 5 h at 37 1C in the dark.
Following hybridization, the cells were washed twice in wash buffer,
resuspended in 0.5ml phosphate buffered saline, and acquired on a
flow cytometer. Although the FISH probes have the potential to detect
both viral RNA and pro-viral DNA, the denaturation protocol that we
used is unlikely to melt duplex DNA. Furthermore, the number of
copies of mRNA will greatly exceed that of DNA; hence, the signal is
almost exclusively due to the detection of viral mRNA.
Measurement of AM phagocytosis, superoxide burst, and bulk
proteolysis. Phagocytosis and enzymatic activities in the phagosomal
compartments of AMs were measured using quantitative flow
cytometry-based reporter bead assays as reported previously.10
In brief, the assays exploit silica beads derivatized with a calibra-
tion fluorochrome (Alexa 405-SE) and the fluorogenic reporter
substrates Oxyburst Green, succinimidyl ester (Molecular Probes,
Eugene, OR) for superoxide burst or DQGreen bovine serum albumin
(Molecular Probes) for bulk proteolysis. When the beads are inter-
nalized by AMs, they gain fluorescence intensity proportional to the
degree of activity in the phagosome. The readout is expressed as a ratio
of the substrate fluorescence to the calibration fluorescence.
For each assay, 100 ml per well of Oxyburst-SE (superoxide burst)
or DQ bovine serum albumin (bulk proteolysis) beads suspension
were added to adherent cells in six-well culture plates. Cells were
collected at two time points, although the duration of the assays was
different. The first time point was 10min after adding beads to wells.
Cells were collected by gentle scrapping into suspension, transferred
to a tube containing 0.5 ml of 3.7% formaldehyde fixative, and
incubated in the dark at room temperature for 15min. The plate was
re-incubated until the second time point (60min for superoxide
burst or 240min for proteolysis) when the cells were collected and
processed as described above. Fixed cells were washed twice in
phosphate buffered saline, resuspended in 0.5ml phosphate buffered
saline, and acquired on a flow cytometer. The readout for
phagocytosis was the proportion of cells that had internalized
the beads after 60min. The readout for the superoxide burst and bulk
proteolysis assays was the Activity Index, which was calculated by
first determining the ratio of MFI of the reporter over calibration
flour at 10- and 60-min, or 240-min time points, and then dividing
the ratio at 60 or 240min by ratio at 10min. To assess AM function
based on the HIV infection status of individual cells, reporter bead
assays were combined with the FISH assay for detecting HIV-
infected cells.
Statistical analyses. Statistical analyses and graphical presentation
were done usingGraphPad Prism 5 (GraphPad Software, La Jolla, CA).
Normally distributed data were analyzed using paired or unpaired
Student’s t-test, whereas non-normally distributed data were analyzed
using Wilcoxon matched-pairs signed-ranked test (paired data) or
Mann–Whitney U-test (non-paired data). One-way analysis of var-
iance with Bonferroni correction was used for multiple comparisons
on paired data. Results are given as medians with IQRs, except for
Activity Indices and the comparison of frequency of HIV-infected
AMs in whole BAL compared with adherent cells, which are given as
means with CIs, and mean with s.e.m., respectively. Differences were
considered statistically significant when Po0.05.
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